PMID- 24039179
OWN - NLM
STAT- MEDLINE
DCOM- 20151026
LR  - 20150224
IS  - 1860-7187 (Electronic)
IS  - 1860-7179 (Linking)
VI  - 8
IP  - 10
DP  - 2013 Oct
TI  - Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
PG  - 1668-72
LID - 10.1002/cmdc.201300289 [doi]
AB  - The human immunodeficiency virus type 1 (HIV-1) uses CD4 and the co-receptor CCR5 
      or CXCR4 in the process of cell entry. The negatively charged extracellular 
      domains of CXCR4 (CXCR4-ED) interact with positive charges on the V3 loop of 
      gp120, facilitating binding via electrostatic interactions. The presence of 
      highly conserved positively charged residues in the V3 loop suggests that 
      CXCR4-ED-derived inhibitors might be broadly effective inhibitors. Synthetic 
      peptide derivatives were evaluated for anti-HIV-1 activity. The 39-mer 
      extracellular N-terminal region (NT) was divided into three fragments with 10-mer 
      overlapping sites (N1-N3), and these linear peptides were synthesized. Peptide N1 
      contains Met 1-Asp 20 and shows significant anti-HIV-1 activity. Extracellular 
      loops 1 and 2 (ECL1 and 2) were mimicked by cyclic peptides C1 and C2, which were 
      synthesized by chemoselective cyclization. Cyclic peptides C1 and C2 show higher 
      anti-HIV-1 activity than their linear peptide counterparts, L1 and L2. The 
      cytotoxicities of C1 and C2 are lower than those of L1 and L2. These results 
      indicate that Met 1-Asp 20 segments of the NT and cyclic peptides of ECL1 and 
      ECL2 are potent anti-HIV-1 drug candidates.
CI  - Copyright (c) 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Hashimoto, Chie
AU  - Hashimoto C
AD  - Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental 
      University, 2-3-10 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062 (Japan).
FAU - Nomura, Wataru
AU  - Nomura W
FAU - Narumi, Tetsuo
AU  - Narumi T
FAU - Fujino, Masayuki
AU  - Fujino M
FAU - Tsutsumi, Hiroshi
AU  - Tsutsumi H
FAU - Haseyama, Masaki
AU  - Haseyama M
FAU - Yamamoto, Naoki
AU  - Yamamoto N
FAU - Murakami, Tsutomu
AU  - Murakami T
FAU - Tamamura, Hirokazu
AU  - Tamamura H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130823
PL  - Germany
TA  - ChemMedChem
JT  - ChemMedChem
JID - 101259013
RN  - 0 (Anti-HIV Agents)
RN  - 0 (HIV Envelope Protein gp120)
RN  - 0 (HIV envelope protein gp120 (305-321))
RN  - 0 (Peptide Fragments)
RN  - 0 (Peptides)
RN  - 0 (Receptors, CXCR4)
SB  - IM
MH  - Amino Acid Sequence
MH  - Anti-HIV Agents/chemical synthesis/*chemistry/pharmacology
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Crystallography, X-Ray
MH  - Drug Design
MH  - HIV Envelope Protein gp120/chemistry/metabolism
MH  - HIV-1/*metabolism
MH  - Humans
MH  - Molecular Sequence Data
MH  - Peptide Fragments/chemistry/metabolism
MH  - Peptides/chemical synthesis/*chemistry/pharmacology
MH  - Protein Structure, Tertiary
MH  - Receptors, CXCR4/chemistry/*metabolism
MH  - Static Electricity
MH  - Virus Integration/drug effects
OTO - NOTNLM
OT  - CXCR4
OT  - HIV-1 entry inhibitors
OT  - antiviral agents
OT  - extracellular domains
OT  - peptides
EDAT- 2013/09/17 06:00
MHDA- 2015/10/27 06:00
CRDT- 2013/09/17 06:00
PHST- 2013/07/01 00:00 [received]
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2015/10/27 06:00 [medline]
AID - 10.1002/cmdc.201300289 [doi]
PST - ppublish
SO  - ChemMedChem. 2013 Oct;8(10):1668-72. doi: 10.1002/cmdc.201300289. Epub 2013 Aug 
      23.